Question explored with the scientific record
Is ivermectin effective in fighting cancer
The short version: ivermectin shrinks tumors in mice, rats, and lab dishes. Nobody has shown it helps a person with cancer.
Every cancer study in this retrieval is animal or cell work. Ivermectin slowed a canine breast tumor in mice by blocking cell-cycle proteins and WNT signaling [1]. It shrank rat gliomas only when packed into nanocapsules, not as plain drug [2]. In human cancer cells it killed cells at low-micromolar doses [3][6], and a platelet-coated nanocrystal version beat triple-negative breast cancer in mice [4]. A review lists it as a repurposing candidate with "limited clinical contexts" [5]. That is the whole evidence base here: no human trial with a real outcome.
The doses matter. The rat glioma work used about 26 micrograms per kilogram, close to human antiparasitic dosing [2]. The cell studies needed concentrations several times higher [3][6]. Whether a person can reach those blood levels safely is unstudied in these records. The retrieval also cannot see unpublished null results, which publication bias hides.
| Model | Result | Human relevance |
|---|---|---|
| Canine tumor, mice [1] | Tumor growth slowed | None proven |
| Rat glioma, plain drug [2] | No significant change | None proven |
| Rat glioma, nanocapsule [2] | 70% smaller tumors | None proven |
| Human cells, lab dish [3][6] | Cell death at 15-30 µM | Dose not shown safe in people |
My call: not proven effective against cancer in humans, and the gap between lab doses and safe human doses is the whole question. Confidence: moderate that the human evidence is absent, not that the drug fails.
Sources used 6
-
Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling
The study shows that repurposed anthelmintic ivermectin inhibits canine mammary tumor growth by causing G1 cell cycle arrest via downregulation of cyclin D1 and CDK4 and by suppressing WNT/β-catenin signaling, with efficacy observed in vitro in canine mammary tumor cell lines an…
DOI: 10.1186/s12917-019-2026-2 -
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression
This study demonstrates nose-to-brain delivery of ivermectin nanocarriers (polymeric nanocapsules and mesoporous silica particles) to suppress glioma growth in a rat model, with intranasal polymeric nanocapsules significantly reducing tumor size and improving histology at a clin…
DOI: 10.1021/acsbiomaterials.5c00642 -
Antiproliferative and Trypanocidal Activity of Ivermectin Bioconjugates
This study synthesizes ten ivermectin bioconjugates with diverse bioactive partners (cinchona alkaloids, nucleosides, metronidazole, betulinic acid, artesunate) using carbonate, urethane, or click-type linkers, and evaluates their antiproliferative activity against four human ca…
DOI: 10.1021/acsomega.5c02998 -
Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management
The study develops biomimetic platelet-membrane camouflaged ivermectin nanocrystals (PMV/Ivm-NC) using a sonoprecipitation method and platelet membrane coating to achieve targeted tumor homing, immunogenic cancer cell death, and enhanced antitumor/antimetastatic effects against …
DOI: 10.1007/s13346-025-02032-2 -
Old wine in new bottles: Drug repurposing in oncology
A comprehensive narrative review detailing how eight non-oncologic drugs (artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide) have demonstrated anticancer activity across in vitro, in vivo, and limited clinical contexts, outlining the…
DOI: 10.1016/j.ejphar.2019.172784 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489